RecruitingCIDPImmunoglobulin DeficiencyChronic Inflammatory Demyelinating Polyneuropathy
IVIG vs SCIG in CIDP
Eligible age
18–65 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.
Sponsor: Rutgers, The State University of New Jersey
You may qualify if…
- ✓ Patients aged \>18 years with a current diagnosis of CIDP (based on European Federation of Neurological sciences / Peripheral Nerve Society CIDP diagnostic criteria).
- ✓ 1:1 conversion of IVIG to SCIG (weekly dose conversion) must fall within 0.2-to-0.4 mg/kg dose for SCIG.
You may not qualify if…
- ✕ Patients receiving IVIG for indications other than CIDP will be excluded.
- ✕ Patients with liver impairment (elevations in liver enzymes of greater than 3 times the upper limit of normal) or reduced renal function (CrCl \< 50 mL/min) will be excluded
- ✕ Active malignancies
- ✕ Diabetes
- ✕ Myasthenia gravis
- ✕ Immunodeficiency
- ✕ Autoimmune disease
Where it's recruiting
New Jersey
New Brunswick
Source: ClinicalTrials.gov · NCT05584631 · last updated 2025-12-11